KRAS and acute lymphoblastic leukemia: Moreover, we identified recurrent ETV6::RUNX1+ subtype-specific SNVs/indels in CCDC168 (11%; 3/28) and UBA2 (11%; 3/28), whereas in the HD BCP-ALL group, subtype-specific recurrent somatic SNVs/indels were observed in KRAS (27%; 8/30), CREBBP (20%; 6/30), FLT3 (17%; 5/30), and PTPN11 (10%; 3/30).